Research advance on SDF-1/CXCR4 axis associated with hematological malignancies: review.
- Author:
Yong-Yuan DAI
1
;
Bao-An CHEN
Author Information
1. Depatment of Hematology, Clinical Medical College, Southeast University, Nanjing 210009, China.
- Publication Type:Journal Article
- MeSH:
Chemokine CXCL12;
biosynthesis;
genetics;
Drug Resistance, Neoplasm;
genetics;
Hematologic Neoplasms;
metabolism;
pathology;
Humans;
Prognosis;
Receptors, CXCR4;
biosynthesis;
genetics;
Signal Transduction;
Stromal Cells;
metabolism
- From:
Journal of Experimental Hematology
2006;14(5):1056-1060
- CountryChina
- Language:Chinese
-
Abstract:
The stromal cell-derived factor 1 (SDF-1) interacts with its receptor CXCR4 to transduction signals, playing important roles in most physiological and pathological processes. It is reported that CXCR4 is highly expressed in many kinds of hematological malignancies and closely related to the prognosis, drug resistance and relapse of diseases. The growth of tumor cells can be inhibited by the anti-SDF-1 antibody or anti- CXCR4 antibody, supporting a new way for the therapy against hematological malignancies. Their expression in relation with prognosis and drug resistance of hematological malignancies are summarized in this review.
